Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Aniracetam | Sabroxy (Oroxylum indicum) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 750-1500 mg/day divided into 2-3 doses | — |
| Timing | With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat) | — |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | — |
| Evidence Level | moderate_human | Emerging |
Potent positive allosteric modulator of AMPA receptors with 5-10x the potency of piracetam, slowing both channel closing rate and microscopic desensitization rates. Also modulates metabotropic glutamate receptors (mGluRs), activates nicotinic acetylcholine receptors, and indirectly boosts dopaminergic and serotonergic neurotransmission, conferring anxiolytic properties.
750-1500 mg/day divided into 2-3 doses
With fat-containing meals (fat-soluble compound; bioavailability increases significantly with dietary fat)
Cycles of 8-12 weeks on, 4 weeks off
Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →